{"id":"topical-timolol-maleate","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Conjunctivitis"},{"rate":null,"effect":"Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients)"}]},"_chembl":{"chemblId":"CHEMBL1200870","moleculeType":"Small molecule","molecularWeight":"432.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body of the eye, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for conditions characterized by elevated eye pressure. The topical formulation allows direct delivery to ocular tissues while minimizing systemic absorption.","oneSentence":"Topical timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:19.949Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07474883","phase":"EARLY_PHASE1","title":"Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Pham Ngoc Thach University of Medicine","startDate":"2026-03-09","conditions":"Post Inflammtory Erythema, Acne Vulgaris, Erythema","enrollment":60},{"nctId":"NCT05479123","phase":"PHASE4","title":"Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-06-23","conditions":"Infantile Hemangioma","enrollment":52},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT07384767","phase":"PHASE2","title":"Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":"Mohs Micrographic Surgery, Excision Margin","enrollment":220},{"nctId":"NCT07335211","phase":"PHASE3","title":"Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Huons Co., Ltd.","startDate":"2026-01","conditions":"Primary Open Angle Glaucoma (POAG), Ocular Hypertension","enrollment":206},{"nctId":"NCT07168902","phase":"PHASE2","title":"Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-10-24","conditions":"Glaucoma","enrollment":228},{"nctId":"NCT02422017","phase":"PHASE2","title":"Topical Timolol Benefit in Venous Ulcers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2015-04","conditions":"Venous Leg Ulcers","enrollment":42},{"nctId":"NCT06993597","phase":"","title":"Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-09-01","conditions":"Glaucoma","enrollment":60},{"nctId":"NCT07154030","phase":"PHASE1","title":"Efficacy Of Combined Microneedling Plus Tretinoin In Treatment Of Stria Rubra","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-09-05","conditions":"Striae","enrollment":300},{"nctId":"NCT03282981","phase":"PHASE3","title":"Beta Adrenergic Antagonist for the Healing of Chronic DFU","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-07-24","conditions":"Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound","enrollment":48},{"nctId":"NCT06941467","phase":"PHASE1","title":"Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-01-03","conditions":"Wound Healing, Mohs Micrographic Surgery","enrollment":102},{"nctId":"NCT06643416","phase":"PHASE3","title":"Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","status":"RECRUITING","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2024-10-09","conditions":"Paronychia, EGFR-TKI, ALK-TKI","enrollment":40},{"nctId":"NCT02053298","phase":"PHASE4","title":"Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-01","conditions":"Open Angle Glaucoma","enrollment":30},{"nctId":"NCT02913612","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2017-05-05","conditions":"Infantile Hemangioma","enrollment":105},{"nctId":"NCT06140186","phase":"PHASE3","title":"Efficacy and Safety of Timolol for TKI Induced Paronychia","status":"UNKNOWN","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2023-04-01","conditions":"Paronychia","enrollment":40},{"nctId":"NCT06152861","phase":"PHASE2","title":"Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Glaukos Corporation","startDate":"2023-11-15","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":250},{"nctId":"NCT01873131","phase":"NA","title":"A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2011-02","conditions":"Hemangioma","enrollment":126},{"nctId":"NCT01752049","phase":"PHASE1, PHASE2","title":"Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2013-05","conditions":"Hereditary Hemorrhagic Telangiectasia","enrollment":5},{"nctId":"NCT01685398","phase":"PHASE3","title":"Topical Timolol for Superficial Infantile Hemangioma","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2012-09","conditions":"Hemangioma","enrollment":48},{"nctId":"NCT03691649","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-14","conditions":"Glaucoma and Ocular Hypertension","enrollment":426},{"nctId":"NCT03691662","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-27","conditions":"Glaucoma and Ocular Hypertension","enrollment":417},{"nctId":"NCT05165082","phase":"NA","title":"The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2021-12-21","conditions":"Paronychia, Epidermal Growth Factor Receptor Inhibitor","enrollment":8},{"nctId":"NCT05597813","phase":"NA","title":"Topical Timolol 0.5% in Atrophic Acne Scar","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2023-03-01","conditions":"Acne Scars - Mixed Atrophic and Hypertrophic","enrollment":30},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03452072","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-08-20","conditions":"Wound of Skin, Wound Heal, Wound Open","enrollment":88},{"nctId":"NCT05114239","phase":"PHASE2","title":"Topical Timolol: a Comparison of Surgical Outcomes","status":"UNKNOWN","sponsor":"Keith G. LeBlanc, Jr, MD","startDate":"2021-04-07","conditions":"Wound Heal","enrollment":30},{"nctId":"NCT05083689","phase":"PHASE2, PHASE3","title":"Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2021-10-06","conditions":"Diabetic Macular Edema","enrollment":62},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT04903366","phase":"","title":"Absorption and Safety of Topical Timolol to Treat Chronic Wounds","status":"COMPLETED","sponsor":"VA Northern California Health Care System","startDate":"2017-11-21","conditions":"Glaucoma, Open-Angle, Chronic Wounds","enrollment":40},{"nctId":"NCT04868175","phase":"NA","title":"Interval Intraocular Pressure in Intravitreal Injection Study","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-10-01","conditions":"Glaucoma, Intraocular Pressure","enrollment":64},{"nctId":"NCT02955849","phase":"EARLY_PHASE1","title":"A Trial of China Laser and Surgery Study Glaucoma in Rural China","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-09","conditions":"Glaucoma","enrollment":200},{"nctId":"NCT03034772","phase":"PHASE2, PHASE3","title":"Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-02-08","conditions":"Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":52},{"nctId":"NCT04288700","phase":"PHASE4","title":"Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-10-01","conditions":"Infantile Hemangioma","enrollment":100},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT02571972","phase":"PHASE2","title":"Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2015-02-01","conditions":"Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema","enrollment":14},{"nctId":"NCT04178863","phase":"PHASE4","title":"CATS Tonometer IOP Reduction Latanoprost Verses Timolol","status":"UNKNOWN","sponsor":"Intuor Technologies, Inc.","startDate":"2018-07-01","conditions":"Glaucoma; Drugs","enrollment":72},{"nctId":"NCT01257698","phase":"NA","title":"Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"Mid Atlantic Retina","startDate":"2010-02","conditions":"Macular Hole, Retinal Detachment","enrollment":21},{"nctId":"NCT01533376","phase":"PHASE1","title":"Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol","status":"TERMINATED","sponsor":"Wills Eye","startDate":"2012-02","conditions":"Sturge Weber Syndrome, Port-wine Mark","enrollment":3},{"nctId":"NCT01749930","phase":"PHASE3","title":"Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT02731287","phase":"PHASE2","title":"Topical Timolol for Infantile Hemangioma in Early Proliferative Phase","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2014-03","conditions":"Hemangioma","enrollment":70},{"nctId":"NCT01749904","phase":"PHASE3","title":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01-31","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01707381","phase":"PHASE2","title":"BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2012-11","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":25},{"nctId":"NCT01843920","phase":"NA","title":"The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble","status":"COMPLETED","sponsor":"Jason Hsu, MD","startDate":"2011-06","conditions":"Scleral Buckling","enrollment":21},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01915940","phase":"PHASE2","title":"Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2013-10-23","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":169},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01147601","phase":"EARLY_PHASE1","title":"Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2010-03","conditions":"Hemangioma, Infant","enrollment":6},{"nctId":"NCT02145884","phase":"PHASE2","title":"Topical Timolol Gel for the Treatment of Infantile Hemangiomas","status":"COMPLETED","sponsor":"Rady Children's Hospital, San Diego","startDate":"2014-05","conditions":"Hemangioma","enrollment":26},{"nctId":"NCT01434849","phase":"PHASE1","title":"Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)","status":"TERMINATED","sponsor":"Alice K. Gong","startDate":"2012-07","conditions":"Infantile Hemangioma, Very Low Birth Weight Infants","enrollment":26},{"nctId":"NCT02214680","phase":"PHASE2","title":"The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2015-10","conditions":"Healthy","enrollment":25},{"nctId":"NCT02522039","phase":"NA","title":"Pupillary Response After Glaucoma Medication","status":"COMPLETED","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2014-05","conditions":"Drug Effect (Glaucoma Drugs)","enrollment":21},{"nctId":"NCT02061735","phase":"","title":"Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2011-10","conditions":"Infantile Hemangiomas","enrollment":118},{"nctId":"NCT00887029","phase":"PHASE4","title":"A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Ophthalmic Consultants Centres, Canada","startDate":"2009-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":54},{"nctId":"NCT00368602","phase":"PHASE2","title":"Beta Blocker for Chronic Wound Healing","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2005-06","conditions":"Ulcer, Burns","enrollment":40},{"nctId":"NCT00275756","phase":"NA","title":"Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2008-09","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01408056","phase":"PHASE2","title":"Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2011-02","conditions":"Infantile Hemangiomas","enrollment":""},{"nctId":"NCT01514734","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-03","conditions":"Glaucoma","enrollment":9},{"nctId":"NCT01923714","phase":"","title":"Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-08","conditions":"Open Angle Glaucoma","enrollment":103},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT01279083","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2011-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":147},{"nctId":"NCT01250457","phase":"PHASE4","title":"Topical Timolol for the Treatment of Benign Vascular Periocular Lesions","status":"WITHDRAWN","sponsor":"Loyola University","startDate":"2010-06","conditions":"Benign Vascular Periocular Lesions","enrollment":""},{"nctId":"NCT00761995","phase":"PHASE4","title":"Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma, Ocular Hypertension","enrollment":200},{"nctId":"NCT01304264","phase":"","title":"Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients","status":"COMPLETED","sponsor":"Lithuanian University of Health Sciences","startDate":"2011-03","conditions":"Open Angle Glaucoma","enrollment":35},{"nctId":"NCT01004900","phase":"PHASE3","title":"Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2009-06","conditions":"Glaucoma","enrollment":90},{"nctId":"NCT00800423","phase":"PHASE3","title":"Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2009-01","conditions":"Corneal Edema, Visual Acuity","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Topical timolol maleate 0.5% drops","timolol","beta blocker","Timoptic"],"phase":"marketed","status":"active","brandName":"Topical timolol maleate","genericName":"Topical timolol maleate","companyName":"Unity Health Toronto","companyId":"unity-health-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}